Business Combinations (Tables)

6 Months Ended

Jun. 30, 2026

The initial aggregate purchase price of this transaction was funded with cash on hand as shown in the table below:


Cash paid to BioMedomics	$	2,865
Transaction expenses	403
Debt paid off	330
Earnout contingent consideration	233
Expense fund	40
Initial aggregate purchase price	$	3,871

The following table summarizes the estimated fair values of the assets acquired and liabilities assumed as of the acquisition date:


Assets Acquired


Other current and non current assets	$	10
Inventory	284
Operating right-of-use assets	120


Developed technology intangible asset	1,900
Goodwill	1,775
Total assets acquired	4,089
Liabilities Assumed
Accounts payable	34
Current liabilities	17
Deferred revenue	72
Operating lease liability	120
Total liabilities assumed	243
Net Assets Acquired	3,846
Estimated fair value of contingent consideration	(233)
Net Cash Paid (net of cash acquired of $25)	$	3,613


	For the Three Months Ended June 30,		For the Six Months Ended June 30,
	2025		2025
Net revenues	$	31,491	$	61,695
Net loss	$	(52,784)	$	(35,771)

Tabular disclosure of business combination. Includes, but is not limited to, recognized asset and liability.